SAVA. I'm certainly not a SAVA "expert" so you might be asking the wrong guy but this is my opinion of today's news. It's certainly intuitive that reducing biomarkers for neurodegeneration and neuroinflammation would be beneficial for AD patients, you're at some point going to have to run cognitive testing. I think its a great first step. I think running a confirmatory trial is the right move. Saves money and the only reason to run such a test is if the FDA says you're potentially on the right path. Also a plus to publish data from a trial in a peer reviewed fasion like this. Some choose not to. Insiders are heavy in this thing as well.
Fact is though, AD is not well understood. Whether or not these 2 biomarkers prove relevant in the long run is still a guess. Not going to predict any share price movement. I missed the bottom but caught the ride from 4+. Currently don't own it but would not mind holding some shares for the long run, as I certainly think they have a shot at success. All is JMHO.
News 
Market Data 
Discover 
